Iovance Biotherapeutics Inc (IOVA) - Total Assets
Based on the latest financial reports, Iovance Biotherapeutics Inc (IOVA) holds total assets worth $904.95 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Iovance Biotherapeutics Inc for net asset value and shareholders' equity analysis.
Iovance Biotherapeutics Inc - Total Assets Trend (2008–2024)
This chart illustrates how Iovance Biotherapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Iovance Biotherapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Iovance Biotherapeutics Inc's total assets of $904.95 Million consist of 50.2% current assets and 49.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.7% |
| Accounts Receivable | $69.34 Million | 7.6% |
| Inventory | $51.52 Million | 5.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $282.40 Million | 31.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Iovance Biotherapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Iovance Biotherapeutics Inc (IOVA) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Iovance Biotherapeutics Inc's current assets represent 50.2% of total assets in 2024, a decrease from 54.4% in 2008.
- Cash Position: Cash and equivalents constituted 12.7% of total assets in 2024, down from 51.8% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 31.0% of total assets.
Iovance Biotherapeutics Inc Competitors by Total Assets
Key competitors of Iovance Biotherapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Iovance Biotherapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.41 | 4.22 | 11.59 |
| Quick Ratio | 3.00 | 3.90 | 11.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $303.31 Million | $380.52 Million | $581.23 Million |
Iovance Biotherapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Iovance Biotherapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.47 |
| Latest Market Cap to Assets Ratio | 1.13 |
| Asset Growth Rate (YoY) | 16.7% |
| Total Assets | $910.43 Million |
| Market Capitalization | $1.03 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Iovance Biotherapeutics Inc's assets above their book value (1.13x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Iovance Biotherapeutics Inc's assets grew by 16.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Iovance Biotherapeutics Inc (2008–2024)
The table below shows the annual total assets of Iovance Biotherapeutics Inc from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $910.43 Million | +16.67% |
| 2023-12-31 | $780.35 Million | +17.53% |
| 2022-12-31 | $663.98 Million | -14.58% |
| 2021-12-31 | $777.33 Million | +1.15% |
| 2020-12-31 | $768.46 Million | +122.96% |
| 2019-12-31 | $344.65 Million | -28.32% |
| 2018-12-31 | $480.82 Million | +209.46% |
| 2017-12-31 | $155.37 Million | -9.61% |
| 2016-12-31 | $171.89 Million | +62.69% |
| 2015-12-31 | $105.65 Million | +127.18% |
| 2014-12-31 | $46.51 Million | +134.01% |
| 2013-12-31 | $19.87 Million | +67467.57% |
| 2012-12-31 | $29.41K | -94.83% |
| 2011-12-31 | $568.43K | -61.09% |
| 2010-12-31 | $1.46 Million | +15067.69% |
| 2009-12-31 | $9.63K | +71.63% |
| 2008-12-31 | $5.61K | -- |
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic me… Read more